Do analysts recommend RLYB or ABEO?

Abeona Therapeutics has a consensus target price of $19.33, indicating a potential upside of 217.46%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts prefer SGMT or RLYB?

Sagimet Biosciences presently has a consensus target price of $29.17, suggesting a potential upside of 184.55%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer SABS or RLYB?

SAB Biotherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 217.46%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe SAB Biotherapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend RLYB or IMRX?

Immuneering has a consensus price target of $17.50, indicating a potential upside of 230.19%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00

Is RLYB or IMRX more profitable?

Immuneering has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Immuneering's return on equity of -27.15% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -40.53% -38.13% Immuneering N/A -27.15% -25.75%

Rallybio (RLYB) Competitors

$16.83 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

RLYB vs. DMAC, ABEO, SGMT, SABS, and IMRX

Should you buy Rallybio stock or one of its competitors? Rallybio's main competitors and comparable companies include DiaMedica Therapeutics (DMAC), Abeona Therapeutics (ABEO), Sagimet Biosciences (SGMT), SAB Biotherapeutics (SABS), and Immuneering (IMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rallybio compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for DiaMedica Therapeutics and 0 mentions for Rallybio. DiaMedica Therapeutics' average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score.

Company	Overall Sentiment
DiaMedica Therapeutics	Neutral
Rallybio	Neutral

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 84.05%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe DiaMedica Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

DiaMedica Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Rallybio	-911.07%	-40.53%	-38.13%

DiaMedica Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

Rallybio has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Rallybio	$860K	103.92	-$8.98M	-$4.34	N/A

Summary

DiaMedica Therapeutics and Rallybio tied by winning 7 of the 14 factors compared between the two stocks.

How does Rallybio compare to Abeona Therapeutics?

Rallybio (NASDAQ:RLYB) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Abeona Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Abeona Therapeutics has higher revenue and earnings than Rallybio. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	103.92	-$8.98M	-$4.34	N/A
Abeona Therapeutics	$25.52M	13.65	$71.18M	-$1.09	N/A

Rallybio has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Abeona Therapeutics has a consensus target price of $19.33, indicating a potential upside of 217.46%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

90.3% of Rallybio shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Abeona Therapeutics had 6 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Abeona Therapeutics and 0 mentions for Rallybio. Abeona Therapeutics' average media sentiment score of 0.12 beat Rallybio's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Rallybio	Neutral
Abeona Therapeutics	Neutral

Summary

Abeona Therapeutics beats Rallybio on 11 of the 16 factors compared between the two stocks.

How does Rallybio compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Rallybio has lower revenue, but higher earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	318.57	-$51.04M	-$1.28	N/A
Rallybio	$860K	103.92	-$8.98M	-$4.34	N/A

In the previous week, Sagimet Biosciences had 3 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Sagimet Biosciences and 0 mentions for Rallybio. Sagimet Biosciences' average media sentiment score of 0.69 beat Rallybio's score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Sagimet Biosciences	Positive
Rallybio	Neutral

Sagimet Biosciences has a beta of 3.37, indicating that its share price is 237% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market.

Sagimet Biosciences presently has a consensus target price of $29.17, suggesting a potential upside of 184.55%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by insiders. Comparatively, 10.3% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sagimet Biosciences has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Sagimet Biosciences' return on equity of -31.96% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Rallybio	-911.07%	-40.53%	-38.13%

Summary

Sagimet Biosciences beats Rallybio on 13 of the 16 factors compared between the two stocks.

How does Rallybio compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

SAB Biotherapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. SAB Biotherapeutics' return on equity of -6.74% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Rallybio	-911.07%	-40.53%	-38.13%

SAB Biotherapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market.

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SAB Biotherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 217.46%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe SAB Biotherapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

SAB Biotherapeutics has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	260.56	$13.27M	-$1.30	N/A
Rallybio	$860K	103.92	-$8.98M	-$4.34	N/A

In the previous week, SAB Biotherapeutics' average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score.

Company	Overall Sentiment
SAB Biotherapeutics	Neutral
Rallybio	Neutral

Summary

SAB Biotherapeutics beats Rallybio on 12 of the 14 factors compared between the two stocks.

How does Rallybio compare to Immuneering?

Rallybio (NASDAQ:RLYB) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Rallybio has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

In the previous week, Immuneering had 2 more articles in the media than Rallybio. MarketBeat recorded 2 mentions for Immuneering and 0 mentions for Rallybio. Immuneering's average media sentiment score of 0.67 beat Rallybio's score of 0.00 indicating that Immuneering is being referred to more favorably in the news media.

Company	Overall Sentiment
Rallybio	Neutral
Immuneering	Positive

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immuneering has a consensus price target of $17.50, indicating a potential upside of 230.19%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immuneering has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Immuneering's return on equity of -27.15% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Immuneering	N/A	-27.15%	-25.75%

Rallybio has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	103.92	-$8.98M	-$4.34	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

Summary

Immuneering beats Rallybio on 12 of the 16 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLYB vs. The Competition

Export

Metric	Rallybio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.37M	$4.01B	$7.33B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-3.88	11.68	272.90	24.25
Price / Sales	103.92	1,352.95	624.39	94.51
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.53	17.38	11.25	6.42
Net Income	-$8.98M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-1.00%	3.03%	2.33%	0.57%
1 Month Performance	3.19%	9.82%	7.72%	4.90%
1 Year Performance	236.06%	55.05%	25.22%	17.06%

Rallybio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLYB Rallybio	0.9119 of 5 stars	$16.83 flat	N/A	+236.1%	$89.37M	$860K	N/A	40	Analyst Upgrade
DMAC DiaMedica Therapeutics	1.3344 of 5 stars	$6.73 +1.8%	$12.00 +78.4%	+6.7%	$363.81M	N/A	N/A	20
ABEO Abeona Therapeutics	2.3872 of 5 stars	$6.27 +1.7%	$19.33 +208.6%	-15.8%	$358.23M	$5.82M	N/A	90	News Coverage Analyst Revision
SGMT Sagimet Biosciences	2.8505 of 5 stars	$10.78 +1.8%	$29.17 +170.7%	+44.2%	$351.86M	$2M	N/A	8	Gap Up
SABS SAB Biotherapeutics	2.0891 of 5 stars	$3.80 +0.2%	$12.00 +216.0%	+75.0%	$345.31M	$1.32M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLYB) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rallybio (RLYB) Competitors

RLYB vs. DMAC, ABEO, SGMT, SABS, and IMRX

How does Rallybio compare to DiaMedica Therapeutics?

Summary

How does Rallybio compare to Abeona Therapeutics?

Summary

How does Rallybio compare to Sagimet Biosciences?

Summary

How does Rallybio compare to SAB Biotherapeutics?

Summary

How does Rallybio compare to Immuneering?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rallybio (RLYB) Competitors

RLYB vs. DMAC, ABEO, SGMT, SABS, and IMRX

How does Rallybio compare to DiaMedica Therapeutics?

Does the media refer more to DMAC or RLYB?

Do insiders & institutionals have more ownership in DMAC or RLYB?

Do analysts rate DMAC or RLYB?

Is DMAC or RLYB more profitable?

Which has more risk and volatility, DMAC or RLYB?

Which has preferable earnings and valuation, DMAC or RLYB?

Summary

How does Rallybio compare to Abeona Therapeutics?

Is RLYB or ABEO more profitable?

Which has preferable earnings and valuation, RLYB or ABEO?

Which has more risk & volatility, RLYB or ABEO?

Do analysts recommend RLYB or ABEO?

Do insiders & institutionals believe in RLYB or ABEO?

Does the media favor RLYB or ABEO?

Summary

How does Rallybio compare to Sagimet Biosciences?

Which has preferable valuation & earnings, SGMT or RLYB?

Does the media prefer SGMT or RLYB?

Which has more risk and volatility, SGMT or RLYB?

Do analysts prefer SGMT or RLYB?

Do institutionals & insiders have more ownership in SGMT or RLYB?

Is SGMT or RLYB more profitable?

Summary

How does Rallybio compare to SAB Biotherapeutics?

Is SABS or RLYB more profitable?

Which has more risk & volatility, SABS or RLYB?

Do insiders & institutionals have more ownership in SABS or RLYB?

Do analysts prefer SABS or RLYB?

Which has stronger earnings and valuation, SABS or RLYB?

Does the media prefer SABS or RLYB?

Summary

How does Rallybio compare to Immuneering?

Which has more volatility and risk, RLYB or IMRX?

Does the media favor RLYB or IMRX?

Do insiders and institutionals believe in RLYB or IMRX?

Do analysts recommend RLYB or IMRX?

Is RLYB or IMRX more profitable?

Which has preferable earnings & valuation, RLYB or IMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools